Commentary: What is the measure of success for atrial fibrillation ablation? Is a reduction in arrhythmia burden sufficient?

J Thorac Cardiovasc Surg. 2023 Apr;165(4):1396-1397. doi: 10.1016/j.jtcvs.2021.04.015. Epub 2021 Apr 20.

Authors

James R Edgerton¹, Ralph J Damiano Jr²

Affiliations

¹ Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, Mo; Baylor Research Institute, Dallas, Tex. Electronic address: james.e@email.wustl.edu.
² Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, Mo.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / surgery
Catheter Ablation* / adverse effects
Humans
Pulmonary Veins* / surgery
Recurrence
Treatment Outcome

Substances

Anti-Arrhythmia Agents

Grants and funding

R01 HL032257/HL/NHLBI NIH HHS/United States